ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE is a distinguished journal that serves as a vital platform for disseminating innovative research and insightful reviews in the field of dermatology and venereology. Published by MASSON EDITEUR, this journal has been a cornerstone for professionals and researchers since its inception in 1977, offering a wealth of knowledge that spans decades. With its ISSN 0151-9638 and E-ISSN 2214-5451, it is indexed within leading databases, ensuring that the published work reaches a broad audience. The journal currently holds a Q3 ranking in the dermatology category, reflecting its commitment to quality and rigorous peer-review processes. While the journal is not open access, it provides an extensive archive of valuable studies that contribute to advancements in skin health and treatment methodologies. Located in Issy-les-Moulineaux, France, ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE continues to attract submissions from esteemed professionals, enhancing its reputation as a crucial resource for those dedicated to the ongoing development of dermatological sciences.

Blood Advances is a premier, peer-reviewed journal published by Elsevier, dedicated to the field of hematology. With an impressive impact factor and classified within the Q1 category of hematology for 2023, it ranks as the 16th out of 137 journals in the Scopus Medicine Hematology category, placing it in the top 88th percentile globally. This influential journal, which has been disseminating invaluable research since its inception in 2017, focuses on advancing knowledge and innovation in blood science, including clinical and laboratory aspects of hematology. Although it offers limited open access features, its comprehensive scope encompasses various topics relevant to both researchers and practitioners. Located in the United States and managed from Amsterdam, Blood Advances provides a vital platform for the dissemination of groundbreaking research, making significant contributions to the understanding and treatment of blood disorders. Researchers, professionals, and students alike will find this journal an essential resource for keeping abreast of the latest developments and advancements in hematology.

ERJ Open Research is a distinguished Open Access journal dedicated to advancing the field of pulmonary and respiratory medicine, published by the European Respiratory Society Journals Ltd. Established in 2015, the journal proudly provides a platform for innovative research and comprehensive studies that address vital questions in respiratory health. With an impressive Q1 ranking in Scopus for Pulmonary and Respiratory Medicine and positioned in the top 73rd percentile among its peers, ERJ Open Research is a critical resource for researchers, clinicians, and students alike. The journal’s commitment to open access ensures that high-quality research is readily available to the global community, fostering collaboration and knowledge-sharing. Whether you are looking to publish groundbreaking findings or stay updated on the latest advancements in respiratory medicine, ERJ Open Research is the premier destination for impactful scholarly contributions.

Pulmonary Circulation is a leading open-access journal published by Wiley, focused on advancing the field of pulmonary and respiratory medicine. Established in 2011, the journal has garnered a prestigious reputation, achieving a Q2 ranking in 2023 among its category and ranking #70 out of 155 in Scopus within the specialty of Medicine – Pulmonary and Respiratory Medicine, reflecting its growing influence and relevance in the scientific community. With its commitment to delivering high-quality, peer-reviewed research, Pulmonary Circulation serves as a vital resource for researchers, clinicians, and students seeking to explore innovative ideas and findings in lung health, pulmonary vascular diseases, and therapeutic approaches. The journal has been open access since 2017, ensuring that groundbreaking research is accessible to a wider audience, thus promoting collaboration and knowledge exchange in this dynamic field. Located in the heart of the United States at 111 River St, Hoboken, NJ 07030-5774, the journal is dedicated to fostering advancements in pulmonary health and addressing real-world challenges facing patients globally.

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

DYSPHAGIA, published by Springer, is a premier journal dedicated to advancing the study of swallowing disorders, a critical area within the fields of Gastroenterology, Otorhinolaryngology, and Speech and Hearing. With an ISSN of 0179-051X and E-ISSN 1432-0460, this journal serves as a vital resource for researchers, clinicians, and students alike, providing cutting-edge research and reviews that inform clinical practice and enhance patient care. As a testament to its influence, DYSPHAGIA holds a Q2 ranking in Gastroenterology and Q1 rankings in both Otorhinolaryngology and Speech and Hearing for 2023. Its Scopus rankings further position it among the leading journals in its field, highlighting its importance and impact within the academic community. The journal publishes contributions that encompass a spectrum of topics related to swallowing, making it an essential platform for disseminating knowledge and fostering innovative solutions in the management of dysphagia. Operating from New York, NY, DYSPHAGIA invites contributions that align with its mission to advance the understanding and treatment of swallowing disorders through rigorous scientific inquiry and discourse.

JOURNAL OF INHERITED METABOLIC DISEASE, published by Wiley, stands at the forefront of research within the fields of genetics and clinical genetics. With an impressive impact factor reflected in its prestigious Q1 category rankings in both Genetics and Clinical Genetics, this journal provides a vital platform for groundbreaking studies and discoveries in inherited metabolic disorders. Since its inception in 1978 and continuing through 2024, it has consistently featured high-quality peer-reviewed articles that advance understanding and treatment options in this critical area of medicine. Researchers and professionals interested in the genetic underpinnings of metabolic diseases will find the journal's contributions invaluable for both their practical applications and theoretical advancements. Although it does not currently offer open access options, subscribers and readers who access the journal will benefit from rich, impactful content and findings that could influence clinical practices and future research initiatives in the field.

Archives of Medical Research is a prestigious scholarly journal dedicated to advancing the field of medicine through the dissemination of high-quality research findings. Published by Elsevier Science Inc., this esteemed journal has garnered significant recognition, boasting a remarkable impact factor and ranking in the top quartile (Q1) of its category, specifically in General Medicine with a Scopus rank of #30 out of 636 journals, placing it in the 95th percentile. Since its inception in 1992, Archives of Medical Research has served as a critical platform for researchers and professionals to share innovative insights and empirical studies that address pressing medical issues and enhance clinical practices. The journal welcomes a range of submissions, ensuring a diverse array of topics that reflect the latest trends and developments in medicine. As the journal continues to push the boundaries of medical research until at least 2025, it remains an essential resource for students, academics, and healthcare professionals striving to make a meaningful impact in the medical community.

Clinical and Experimental Medicine is a leading journal published by Springer-Verlag Italia SRL, dedicated to advancing the understanding of the intricate relationships between biomedical research and clinical applications. Since its inception in 2001, the journal has garnered an esteemed reputation, achieving Q1 quartile rankings in 2023 in both Biochemistry, Genetics and Molecular Biology (miscellaneous) and Medicine (miscellaneous), establishing itself as a key resource for researchers and practitioners alike. With an impactful contribution reflected in its Scopus rankings, particularly a #81/221 rank in the General Biochemistry, Genetics and Molecular Biology category, Clinical and Experimental Medicine serves as a rich platform for peer-reviewed articles that bridge theory and practice across diverse medical disciplines. The journal embraces Open Access options, broadening the accessibility of groundbreaking research to a global audience, thereby fostering collaboration and innovation. Located in Milan, Italy, it continually endeavors to enrich knowledge and share valuable insights essential for the advancement of health sciences.

Intractable & Rare Diseases Research is a pioneering journal dedicated to advancing the understanding and treatment of rare and intractable diseases. Published by INT RESEARCH & COOPERATION ASSOC BIO & SOCIO-SCIENCES ADVANCEMENT in Japan, this esteemed journal serves as a critical platform for researchers, clinicians, and healthcare professionals to share groundbreaking findings and developments in the field. With its established Scopus ranking of #238 out of 636 in the General Medicine category, placing it in the 62nd percentile, and its classification in the Q3 quartile for 2023, it is recognized as a significant contributor to the literature on rare diseases. Operating without an open-access model, the journal ensures high-quality content cultivated through rigorous peer-review processes. Through its scope spanning from 2012 to 2024, the journal aspires to bridge gaps in knowledge and foster collaboration among interdisciplinary researchers, ultimately aiming to improve patient outcomes and enhance public health concerning these challenging conditions.